SPONSOR
Bayer
Total Trials
6
Recruiting
6
Phases
Phase 1, Phase 1, Phase 2, Phase 3
Conditions studied: Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Low-volume MetastasisAdvanced or Recurrent Solid Tumor Harboring an NTRK Gene FusionAdvanced Solid Tumors Harboring KRAS G12C MutationMTAP-deleted Solid TumorsChronic Heart FailureEndometrial Hyperplasia
NCT06661122
Recruiting
A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
NCT04945330
Recruiting
NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes
Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion
NCT06659341 Phase 1
Recruiting
A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation
Advanced Solid Tumors Harboring KRAS G12C Mutation
NCT06914128 Phase 1, Phase 2
Recruiting
A First-in-human Study to Learn How Safe BAY 3713372 is and How it Works in Participants With MTAP-deleted Solid Tumors
MTAP-deleted Solid Tumors
NCT05666518
Recruiting
A Study to Learn More About the Safety of the Drug Vericiguat in Japanese People With Chronic Heart Failure Who Will be Receiving Vericiguat Under Real-world Conditions
Chronic Heart Failure
NCT06904274 Phase 3
Recruiting
Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months
Endometrial Hyperplasia